Acute Renal Failure Program

Acute renal failure occurs in approximately 1% of hospitalized patients. This decline in renal function, often brought on by infections, various toxins, and medications, is associated with an increase in complications and death.

MCG's Renal Division is nationally recognized as a leader in the prevention and treatment of acute renal failure. We identify those at risk and use state of the art measures to prevent kidney injury.  For those who need temporary therapy to replace renal function, we offer all modes of dialysis. In patients with stable blood pressures, intermittent dialysis using Fresenius 2008 K machines is the treatment most used.  For critically ill patients, we institute Slow Extended Dialysis (SLED).  MCG is one of the leaders in this technology. We have also developed new therapies using SLED and high volume hemofiltration to treat patients with overwhelming infections.

Because of our reputation, we have been asked to participate in major national clinical trials.  We were one of 11 institutions to participate in a study looking at the feasibility of using a bioartificial kidney made from human proximal tubule cells in the treatment of acute renal failure.  We are also participating in a combined VA/NIH study comparing daily dialysis to conventional three times a week dialysis in the critically ill.